Retatrutide for Weight Loss
The most powerful weight loss peptide ever studied in clinical trials. Average 28.7% body weight reduction over 48 weeks.
28.7%
Avg Weight Loss
48 weeks
Trial Duration
Weekly
Frequency
Phase 3
Status
How Retatrutide Causes Weight Loss
GLP-1 Agonism
Suppresses appetite dramatically via brain satiety centers. Slows gastric emptying — you feel full faster and longer. Reduces "food noise" — obsessive thoughts about eating.
GIP Agonism
Enhances the GLP-1 effect and improves insulin response. GIP agonism appears to reduce GLP-1-driven nausea, making the combination better tolerated than GLP-1 alone.
Glucagon Agonism
The key differentiator from Tirzepatide and Semaglutide. Directly increases metabolic rate (thermogenesis) and fat oxidation, particularly visceral fat. This is why Retatrutide loses significantly more weight than dual-agonists.
Titration Protocol
| Phase | Dose | Duration | Notes |
|---|---|---|---|
| Starting | 2mg | Weeks 1–4 | Assess tolerance, manage nausea |
| Titration 1 | 4mg | Weeks 5–8 | Appetite suppression intensifies |
| Titration 2 | 8mg | Weeks 9–16 | Maximum weight loss phase |
| Maintenance | 8–12mg | Ongoing | Individualize to response |
Expected Results Timeline
Nausea is common. Appetite noticeably reduces. First 1–2kg may be lost from reduced caloric intake and water weight.
Nausea subsides. Food noise quietens significantly. Steady weight loss begins — typically 2–4kg in first full month.
Weight loss accelerates at higher dose. Often 1–2kg per week if dietary adjustments maintained. Visceral fat begins to reduce visibly.
15–25% body weight reduction achievable. Body composition improves dramatically. Slowdown near target weight is normal.
Managing Nausea (Most Common Side Effect)
Muscle Preservation: Rapid weight loss can cause muscle loss alongside fat loss. Maintain protein intake of 1.6–2g per kg bodyweight and include resistance training to preserve lean mass during treatment.